Parallax Volatility Advisers
AXSM icon

Parallax Volatility Advisers’s Axsome Therapeutics AXSM Stock Holding History

Parallax Volatility Advisers’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed -$4K – 2859
2022
Q3 		$4K Buy
+100
New +$5K ﹤0.01% 2911
2020
Q2 		– Sell
-500
Closed -$30K – 2696
2020
Q1 		$30K Buy
+500
New +$40.7K ﹤0.01% 2307

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parallax Volatility Advisers's AXSM Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Axsome Therapeutics (AXSM) in Q4 2022, closing a stake of 9,565 shares — an estimated $427K sold.

Parallax Volatility Advisers first reported a position in AXSM in Q1 2019 and held it in 3 quarters. The position peaked at $2.38M in Q1 2019. 219 funds tracked by Wall St. Rank hold AXSM as of Q4 2022.

  • Parallax Volatility Advisers reported no remaining Axsome Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 9,565 Axsome Therapeutics shares in Q4 2022, an estimated $427K.
  • Parallax Volatility Advisers first reported a position in Axsome Therapeutics in Q1 2019 and held it in 3 quarters.
  • Parallax Volatility Advisers's Axsome Therapeutics position peaked at $2.38M in Q1 2019.
  • 219 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.